Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study

Abstract

BackgroundImmune monitoring by flow cytometry is a fast and highly informative way of studying the effects of novel therapeutics aimed at reducing transplant rejection or treating autoimmune diseases. The ONE Study consortium has recently initiated a series of clinical trials aimed at using different cell therapies to promote tolerance to renal allografts. To compare the effectiveness of different cell therapies, the consortium developed a robust immune monitoring strategy, including procedures for whole blood (WB) leukocyte subset profiling by flow cytometry.MethodsSix leukocyte profiling panels computing 7- to 9-surface marker antigens for monitoring the major leukocyte subsets as well as characteristics of T cell, B cell, and dendritic cell (DC) subsets were designed. The precision and variability of these panels were estimated. The assay was standardized within eight international laboratories using Flow-Set Pro beads for mean fluorescence intensity target definition and the flow cytometer setup procedure. Standardization was demonstrated by performing inter-site comparisons.ResultsOptimized methods for sample collection, storage, preparation, and analysis were established, including protocols for gating target subsets. WB specimen age testing demonstrated that staining must be performed within 4 hours of sample collection to keep variability low, meaning less than or equal to 10% for the majority of defined leukocyte subsets. Inter-site comparisons between all participating centers testing shipped normal WB revealed good precision, with a variability of 0.05% to 30% between sites. Intra-assay analyses revealed a variability of 0.05% to 20% for the majority of subpopulations. This was dependent on the frequency of the particular subset, with smaller subsets showing higher variability. The intra-assay variability performance defined limits of quantitation (LoQ) for subsets, which will be the basis for assessing statistically significant differences achieved by the different cell therapies.ConclusionsLocal performance and central analysis of the ONE Study flow cytometry panel yields acceptable variability in a standardized assay at multiple international sites. These panels and procedures with WB allow unmanipulated analysis of changes in absolute cell numbers of leukocyte subsets in single- or multicenter clinical trials. Accordingly, we propose the ONE Study panel may be adopted as a standardized method for monitoring patients in clinical trials enrolling transplant patients, particularly trials of novel tolerance promoting therapies, to facilitate fair and meaningful comparisons between trials.

Eight-color immunophenotyping of T-, B-, and NK-cell subpopulations for characterization of chronic immunodeficiencies

“…Using a flow-cytometric approach, the present study describes validated protocols for the detection and Comprehensive flow cytometric immunophenotyping panels were already published in the current literature and are well known (36)(37)(38). In the CLIP panel (comprehensive leukocyte immunophenotyping panel) (36), ten 15-color panels were designed to measure T-, B-, NK-, dendric cells as well as monocytes.…”

Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development

“…The availability of contract laboratories in the geographic locale of the study is an important consideration since sample shipment across borders can present numerous logistical problems, the net result being poor sample quality due to exceeding stability limitations. Careful assessment of a contract research organization's global footprint is essential, and the performance of each local laboratory should be assessed directly as part of the prestudy CRO selection process 55.…”

Immunomonitoring Lymphocyte Subpopulations in Multiple Sclerosis Patients

“…Recent advances in the development of multiparametric flow cytometry have made detailed characterization of lymphocyte subsets possible in whole blood or isolated peripheral blood mononuclear cells (PBMC) of healthy donors and patients, and it has been presented as a powerful tool for immunomonitoring of response to treatment (5,6). Concurrent to this development, several international consortia have been created to standardize immune-monitoring using flow cytometry for immunemediated diseases, transplantation, and hematological diseases, for potential use in clinical settings (7)(8)(9).…”